Increased fracture rate in women with breast cancer: a review of the hidden risk

[1] Kanis JA(1999)A high incidence of vertebral fracture in women with breast cancer Br J Cancer 79 1179-1181

[2] McCloskey EV(2007)Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study J Bone Miner Res 22 135-141

[3] Powles T(1997)Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens Br J Cancer 75 602-605

[4] Paterson AHG(2005)Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study Arch Intern Med 165 552-558

[5] Ashley S(2010)Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study Breast Cancer Res Treat 124 153-161

[6] Spector T(2010)Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 1135-1141

[7] McCloskey EV(2009)Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann Oncol 20 1489-1498

[8] Beneton M(2009)Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Crit Rev Oncol Hematol 69 73-82

[9] Charlesworth D(1998)Endogenous hormones and the risk of hip and vertebral fractures among older women N Engl J Med 339 733-738

[10] Kayan K(2006)Management of age-related osteoporosis and prevention of associated fractures Ther Clin Risk Manag 2 281-295

[1] Kanis JA(1999)A high incidence of vertebral fracture in women with breast cancer Br J Cancer 79 1179-1181

[2] McCloskey EV(2007)Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study J Bone Miner Res 22 135-141

[3] Powles T(1997)Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens Br J Cancer 75 602-605

[4] Paterson AHG(2005)Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study Arch Intern Med 165 552-558

[5] Ashley S(2010)Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study Breast Cancer Res Treat 124 153-161

[6] Spector T(2010)Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 1135-1141

[7] McCloskey EV(2009)Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann Oncol 20 1489-1498

[8] Beneton M(2009)Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Crit Rev Oncol Hematol 69 73-82

[9] Charlesworth D(1998)Endogenous hormones and the risk of hip and vertebral fractures among older women N Engl J Med 339 733-738

[10] Kayan K(2006)Management of age-related osteoporosis and prevention of associated fractures Ther Clin Risk Manag 2 281-295